US Nuclear Secures Its Position at Bioelectronics Startup Grapheton
US Nuclear Secures Its Position at Bioelectronics Startup Grapheton
Los Angeles, CA. October 19, 2020 – In addition to US Nuclear’s (OTC: UCLE) 40% stake in Grapheton, CEO Robert Goldstein has recently taken a seat on Grapheton’s board of directors and will now serve as Chief Strategy Officer. As Chief Strategy Officer for Grapheton, Robert Goldstein will help the business become a leader in the new field of bioelectronics and will cement the partnership between US Nuclear and Grapheton.
Grapheton’s unique, patented bioelectronic implants lead the world in bio-compatibility and longevity. Bioelectronics is becoming popular among researchers and doctors, and the bioelectronics market is likely to experience tremendous growth in the near future. In recent years, there have been numerous breakthroughs using bioelectronics technology. A notable example, bioelectronic devices have been researched and used in clinical trials to treat rheumatoid arthritis and Crohn’s disease by electrically stimulating the vagus nerve to control inflammation and the immune response.
Bioelectronics has the potential to become a vital branch of medical treatment. Medical care, in general, has made many advances in recent years, but there are a great many diseases, conditions, injuries, and remaining unmet patient needs that still need to be urgently addressed.
(more…)